Cargando…

Efficacy of LD Bio Aspergillus ICT Lateral Flow Assay for Serodiagnosis of Chronic Pulmonary Aspergillosis

Background: The diagnosis of CPA relies on the detection of the IgG Aspergillus antibody, which is not freely available, especially in resource-poor settings. Point-of-care tests like LDBio Aspergillus ICT lateral flow assay, evaluated in only a few studies, have shown promising results for the diag...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Animesh, Chowdhury, Mohit, Sachdev, Janya, Sethi, Prayas, Meena, Ved Prakash, Singh, Gagandeep, Xess, Immaculata, Vyas, Surabhi, Khan, Maroof Ahmad, Sinha, Sanjeev, Denning, David W., Wig, Naveet, Kabra, Sushil Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029852/
https://www.ncbi.nlm.nih.gov/pubmed/35448631
http://dx.doi.org/10.3390/jof8040400
_version_ 1784692001176813568
author Ray, Animesh
Chowdhury, Mohit
Sachdev, Janya
Sethi, Prayas
Meena, Ved Prakash
Singh, Gagandeep
Xess, Immaculata
Vyas, Surabhi
Khan, Maroof Ahmad
Sinha, Sanjeev
Denning, David W.
Wig, Naveet
Kabra, Sushil Kumar
author_facet Ray, Animesh
Chowdhury, Mohit
Sachdev, Janya
Sethi, Prayas
Meena, Ved Prakash
Singh, Gagandeep
Xess, Immaculata
Vyas, Surabhi
Khan, Maroof Ahmad
Sinha, Sanjeev
Denning, David W.
Wig, Naveet
Kabra, Sushil Kumar
author_sort Ray, Animesh
collection PubMed
description Background: The diagnosis of CPA relies on the detection of the IgG Aspergillus antibody, which is not freely available, especially in resource-poor settings. Point-of-care tests like LDBio Aspergillus ICT lateral flow assay, evaluated in only a few studies, have shown promising results for the diagnosis of CPA. However, no study has compared the diagnostic performances of LDBio LFA in setting of tuberculosis endemic countries and have compared it with that of IgG Aspergillus. Objectives: This study aimed to evaluate the diagnostic performances of LDBio LFA in CPA and compare it with existing the diagnostic algorithm utilising ImmunoCAP IgG Aspergillus. Methods: Serial patients presenting with respiratory symptoms (cough, haemoptysis, fever, etc.) for >4 weeks were screened for eligibility. Relevant investigations, including direct microscopy and culture of respiratory secretions, IgG Aspergillus, chest imaging, etc., were done according to existing algorithm. Serums of all patients were tested by LDBio LFA and IgG Aspergillus (ImmunoCAP Asp IgG) and their diagnostic performances were compared. Results: A total of 174 patients were included in the study with ~66.7% patients having past history of tuberculosis. A diagnosis of CPA was made in 74 (42.5%) of patients. The estimated sensitivity and specificity of LDBio LFA was 67.6% (95% CI: 55.7–78%) and 81% (95% CI: 71.9–88.2%), respectively, which increased to 73.3% (95% CI: 60.3–83.9%) and 83.9% (95% CI: 71.7–92.4%), respectively, in patients with a past history of tuberculosis. The sensitivity and specificity of IgG Aspergillus was 82.4% (95% CI: 71.8–90.3%) and 82% (95% CI: 73.1–89%); 86.7% (95% CI: 75.4–94.1%) and 80.4% (95% CI: 67.6–89.8%), in the whole group and those with past history of tuberculosis, respectively. Conclusions: LDBio LFA is a point-of-care test with reasonable sensitivity and specificity. However, further tests may have to be done to rule-in or rule-out the diagnosis of CPA in the appropriate setting.
format Online
Article
Text
id pubmed-9029852
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90298522022-04-23 Efficacy of LD Bio Aspergillus ICT Lateral Flow Assay for Serodiagnosis of Chronic Pulmonary Aspergillosis Ray, Animesh Chowdhury, Mohit Sachdev, Janya Sethi, Prayas Meena, Ved Prakash Singh, Gagandeep Xess, Immaculata Vyas, Surabhi Khan, Maroof Ahmad Sinha, Sanjeev Denning, David W. Wig, Naveet Kabra, Sushil Kumar J Fungi (Basel) Article Background: The diagnosis of CPA relies on the detection of the IgG Aspergillus antibody, which is not freely available, especially in resource-poor settings. Point-of-care tests like LDBio Aspergillus ICT lateral flow assay, evaluated in only a few studies, have shown promising results for the diagnosis of CPA. However, no study has compared the diagnostic performances of LDBio LFA in setting of tuberculosis endemic countries and have compared it with that of IgG Aspergillus. Objectives: This study aimed to evaluate the diagnostic performances of LDBio LFA in CPA and compare it with existing the diagnostic algorithm utilising ImmunoCAP IgG Aspergillus. Methods: Serial patients presenting with respiratory symptoms (cough, haemoptysis, fever, etc.) for >4 weeks were screened for eligibility. Relevant investigations, including direct microscopy and culture of respiratory secretions, IgG Aspergillus, chest imaging, etc., were done according to existing algorithm. Serums of all patients were tested by LDBio LFA and IgG Aspergillus (ImmunoCAP Asp IgG) and their diagnostic performances were compared. Results: A total of 174 patients were included in the study with ~66.7% patients having past history of tuberculosis. A diagnosis of CPA was made in 74 (42.5%) of patients. The estimated sensitivity and specificity of LDBio LFA was 67.6% (95% CI: 55.7–78%) and 81% (95% CI: 71.9–88.2%), respectively, which increased to 73.3% (95% CI: 60.3–83.9%) and 83.9% (95% CI: 71.7–92.4%), respectively, in patients with a past history of tuberculosis. The sensitivity and specificity of IgG Aspergillus was 82.4% (95% CI: 71.8–90.3%) and 82% (95% CI: 73.1–89%); 86.7% (95% CI: 75.4–94.1%) and 80.4% (95% CI: 67.6–89.8%), in the whole group and those with past history of tuberculosis, respectively. Conclusions: LDBio LFA is a point-of-care test with reasonable sensitivity and specificity. However, further tests may have to be done to rule-in or rule-out the diagnosis of CPA in the appropriate setting. MDPI 2022-04-14 /pmc/articles/PMC9029852/ /pubmed/35448631 http://dx.doi.org/10.3390/jof8040400 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ray, Animesh
Chowdhury, Mohit
Sachdev, Janya
Sethi, Prayas
Meena, Ved Prakash
Singh, Gagandeep
Xess, Immaculata
Vyas, Surabhi
Khan, Maroof Ahmad
Sinha, Sanjeev
Denning, David W.
Wig, Naveet
Kabra, Sushil Kumar
Efficacy of LD Bio Aspergillus ICT Lateral Flow Assay for Serodiagnosis of Chronic Pulmonary Aspergillosis
title Efficacy of LD Bio Aspergillus ICT Lateral Flow Assay for Serodiagnosis of Chronic Pulmonary Aspergillosis
title_full Efficacy of LD Bio Aspergillus ICT Lateral Flow Assay for Serodiagnosis of Chronic Pulmonary Aspergillosis
title_fullStr Efficacy of LD Bio Aspergillus ICT Lateral Flow Assay for Serodiagnosis of Chronic Pulmonary Aspergillosis
title_full_unstemmed Efficacy of LD Bio Aspergillus ICT Lateral Flow Assay for Serodiagnosis of Chronic Pulmonary Aspergillosis
title_short Efficacy of LD Bio Aspergillus ICT Lateral Flow Assay for Serodiagnosis of Chronic Pulmonary Aspergillosis
title_sort efficacy of ld bio aspergillus ict lateral flow assay for serodiagnosis of chronic pulmonary aspergillosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029852/
https://www.ncbi.nlm.nih.gov/pubmed/35448631
http://dx.doi.org/10.3390/jof8040400
work_keys_str_mv AT rayanimesh efficacyofldbioaspergillusictlateralflowassayforserodiagnosisofchronicpulmonaryaspergillosis
AT chowdhurymohit efficacyofldbioaspergillusictlateralflowassayforserodiagnosisofchronicpulmonaryaspergillosis
AT sachdevjanya efficacyofldbioaspergillusictlateralflowassayforserodiagnosisofchronicpulmonaryaspergillosis
AT sethiprayas efficacyofldbioaspergillusictlateralflowassayforserodiagnosisofchronicpulmonaryaspergillosis
AT meenavedprakash efficacyofldbioaspergillusictlateralflowassayforserodiagnosisofchronicpulmonaryaspergillosis
AT singhgagandeep efficacyofldbioaspergillusictlateralflowassayforserodiagnosisofchronicpulmonaryaspergillosis
AT xessimmaculata efficacyofldbioaspergillusictlateralflowassayforserodiagnosisofchronicpulmonaryaspergillosis
AT vyassurabhi efficacyofldbioaspergillusictlateralflowassayforserodiagnosisofchronicpulmonaryaspergillosis
AT khanmaroofahmad efficacyofldbioaspergillusictlateralflowassayforserodiagnosisofchronicpulmonaryaspergillosis
AT sinhasanjeev efficacyofldbioaspergillusictlateralflowassayforserodiagnosisofchronicpulmonaryaspergillosis
AT denningdavidw efficacyofldbioaspergillusictlateralflowassayforserodiagnosisofchronicpulmonaryaspergillosis
AT wignaveet efficacyofldbioaspergillusictlateralflowassayforserodiagnosisofchronicpulmonaryaspergillosis
AT kabrasushilkumar efficacyofldbioaspergillusictlateralflowassayforserodiagnosisofchronicpulmonaryaspergillosis